Development of a novel point-of-care blood fingerpick device that identifies adult chemotherapy patients requiring emergency admission for suspected neutropenic sepsis
Technology highlight: The NeutroCheck device will rapidly identify chemotherapy patients at risk of a life-threatening complication called neutropenic sepsis. Through better triaging, Neutrocheck has the potential to save hundreds of UK lives per year, free-up healthcare resources, and make patients’ lives easier, simpler, and better.
Technology summary: Even a mild illness can put chemotherapy patients at risk of developing a condition called neutropenic sepsis. Neutropenic sepsis is a life-threatening emergency, so patients are rushed to hospital if they show any symptoms. However, 50% of patients turn out not to have the condition, and therefore suffer unnecessary stress and receive unnecessary antibiotics. NeutroCheck is a fast, reliable and low-cost device to test for suspected neutropenic sepsis at home. NeutroCheck enables rapid management of the condition for those who test positive, and gives peace of mind to those who don’t. Neutrocheck aims to improve patient safety and quality of life, reducing antibiotic wastage, and empowering doctors to treat their patients efficiently.